Stock Track | PROCEPT BioRobotics Soars 15.15% After-Hours on Strong Q1 Earnings Beat and Upbeat Guidance

Stock Track04-30

PROCEPT BioRobotics Corporation (PRCT) saw its stock price surge 15.15% in after-hours trading on Wednesday, following the release of its first-quarter 2026 financial results.

The surgical robotics company reported quarterly revenue of $83.132 million, beating analyst estimates of $80.506 million and representing a 20% year-over-year increase. Adjusted EBITDA loss of $18.122 million also came in better than the expected $18.7 million loss, driven by strong U.S. system sales, improved pricing, and a 30% increase in U.S. procedures.

Investors reacted positively to the company's maintained full-year 2026 guidance, which projects revenue growth of 27% to 33%, and to the recent FDA clearance of its second-generation FirstAssist AI software for Aquablation therapy, which enhances the capabilities of its HYDROS robotic system.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment